Neurophage Pharmaceuticals
HomeAbout UsOur ScienceNewsCareersContact Us

Our Science

. . . . . . . . . . . . . . . . . . . . . .

GAIM Technology

. . . . . . . . . . . . . . . . . . . . . .

Protein Misfolding Diseases

Alzheimer's Disease

Parkinson's Disease

. . . . . . . . . . . . . . . . . . . . . .

Lead Candidate

. . . . . . . . . . . . . . . . . . . . . .

Resource Links

. . . . . . . . . . . . . . . . . . . . . .

Papers and Posters

. . . . . . . . . . . . . . . . . . . . . .

 

 

 

NeuroPhage’s lead drug candidate, NPT088, is in preclinical development for the treatment of neurodegenerative diseases. NPT088 is an immunoglobulinfusion protein, based on the Company’s breakthrough GAIM (general amyloid interaction motif) technology.

NPT088 can simultaneously target multiple misfolded proteins (Aβ, Tau, α-synuclein) at key stages of amyloid assembly, including small aggregates (oligomers) to amyloid fibers. Preclinical data show that NPT088 potently reduces levels of pre-existing amyloid deposits, the end stage of misfolded protein aggregation, as well as the earlier stage oligomer assemblies, considered to be highly neurotoxic. This broad acting activity is unique among disease-modifying approaches for AD, PD, and other neurodegenerative diseases.